New hope for rare skin condition: apremilast trial shows promise
NCT ID NCT05875714
First seen Nov 01, 2025 · Last updated May 14, 2026 · Updated 28 times
Summary
This study tested a drug called apremilast (Otezla) in 8 people with chronic, treatment-resistant erythema multiforme, a painful skin and mucous membrane condition. The goal was to see if the drug could reduce the number and pain of flare-ups over 6 months. Participants took the medication and were monitored for changes in symptoms compared to before treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ERYTHEMA MULTIFORME are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Perelman Center For Advanced Medicine
Philadelphia, Pennsylvania, 19104, United States
Conditions
Explore the condition pages connected to this study.